Astra Zeneca 3Q Revenues: $6.7 billion (-19%) 3Q Earnings: $1.5 billion (-18%) YTD Revenues: $20.7 billion (-17%) YTD Earnings: $4.8 billion (-21%) Comments: U.S. revenues were down 19% in the quarter, due to the loss of exclusivity for Seroquel IR. Revenue in the Rest of World (ROW) was down 12% and revenue in western Europe was down 20%, due to patent expirations for Seroquel IR, Atacand, Nexium and Merrem, accounting for 70% of the revenue decline. Crestor sales were down 2% to $1.5 bill...